<a href="https://x.com/search?q=%24REGN&src=cashtag_click">$REGN</a> has released its Q4 2024 earnings, showing notable growth and strong performance across its key products like Dupixent, Libtayo, and EYLEA. Key stats indicate a 10% increase in total revenues to $3.8 billion and an earnings per share rise to $12.07, highlighting robust profitability. However, EYLEA is facing competitive pressure which could impact future growth.

$REGN has released its Q4 2024 earnings, showing notable growth and strong performance across its key products like Dupixent, Libtayo, and EYLEA. Key stats indicate a 10% increase in total revenues to $3.8 billion and an earnings per share rise to $12.07, highlighting robust profitability. However, EYLEA is facing competitive pressure which could impact future growth.

<a href="https://x.com/search?q=%24REGN&amp;src=cashtag_click" rel="noopener noreferrer">$REGN</a> has released its Q4 2024 earnings, showing notable growth and strong performance across its key products like Dupixent, Libtayo, and EYLEA. Key stats indicate a 10% increase in total revenues to $3.8 billion and an earnings per share rise to $12.07, highlighting robust profitability. However, EYLEA is facing competitive pressure which could impact future growth.

Regeneron Pharmaceuticals, Inc. (REGN), 2024 Q4 earnings digest

Discussions on the latest quarterly earnings reports from growth and value stocks.

Share Regeneron Pharmaceuticals, Inc. (REGN), 2024 Q4 earnings digest

Sign up to save your podcasts

Regeneron Pharmaceuticals, Inc. (REGN), 2024 Q4 earnings digest

Regeneron Pharmaceuticals, Inc. (REGN), 2024 Q4 earnings digest